LianBio
Dr. Kumar, Ph.D., is a co-founder and has served as Chief Executive Officer and a member of the board of directors at BridgeBio since April 2015. Dr. Kumar has also served as the Chief Executive Officer of Eidos Therapeutics, Inc. (Nasdaq: EIDX), a clinical stage biopharmaceutical company, and a member of Eidos Therapeutics’ board of directors since March 2016. Prior to that, he served as the interim vice president of business development at MyoKardia, Inc. (Nasdaq: MYOK). Prior to that, Dr. Kumar was a principal at Third Rock Ventures and an associate principal at McKinsey & Company.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
LianBio
LianBio’s mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in China and major Asian markets through partnerships that provide access to the best science-driven therapeutic discoveries.